Paradigm Biopharmaceuticals Limited

ASX:PAR Rapporto sulle azioni

Cap. di mercato: AU$98.1m

Paradigm Biopharmaceuticals Crescita futura

Future criteri di controllo 0/6

Si prevede che Paradigm Biopharmaceuticals aumenterà gli utili a una percentuale pari a 8.8% all'anno. Si prevede che l'EPS crescerà a una percentuale pari a 56.9% all'anno.

Informazioni chiave

8.8%

Tasso di crescita degli utili

56.9%

Tasso di crescita dell'EPS

Biotechs crescita degli utili15.3%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento08 May 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22
Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17
Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22
Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24
We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28
Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29
When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Previsioni di crescita degli utili e dei ricavi

ASX:PAR - Stime future degli analisti e dati finanziari passati (AUD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
6/30/2024N/A-59-66-66N/A
3/31/20240-64-72-72N/A
12/31/20230-69-78-78N/A
9/30/20230-60-62-62N/A
6/30/2023N/A-52-45-45N/A
3/31/20230-48-39-39N/A
12/31/20220-44-33-33N/A
9/30/20220-42-33-33N/A
6/30/20220-39-32-32N/A
3/31/20220-40-32-32N/A
12/31/20210-41-32-32N/A
9/30/20210-37-34-34N/A
6/30/20210-34-35-35N/A
3/31/20210-31-29-29N/A
12/31/2020-1-28-24-23N/A
9/30/20200-20-17-17N/A
6/30/2020N/A-12-10-10N/A
3/31/20202-14-10-10N/A
12/31/20194-16-10-10N/A
9/30/20193-16-8-8N/A
6/30/20193-16-6-6N/A
3/31/20193-11-7-7N/A
12/31/20183-7-7-7N/A
9/30/20183-7-6-6N/A
6/30/20183-6-6-6N/A
3/31/20182-6N/A-4N/A
12/31/20172-5N/A-3N/A
9/30/20172-5N/A-4N/A
6/30/20172-4N/A-4N/A
3/31/20172-4N/A-5N/A
12/31/20161-4N/A-6N/A
9/30/20161-4N/A-5N/A
6/30/20161-3N/A-4N/A
3/31/20161-3N/A-3N/A
12/31/20150-2N/A-1N/A
9/30/20150-2N/A-1N/A
6/30/2015N/A-2N/A-1N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che PAR rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che PAR rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che PAR rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di PAR cresceranno più rapidamente del mercato Australian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di PAR cresceranno più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di PAR è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita